Focus: TX01 (pre-registration)
Niemann-Pick type C Disease
Niemann-Pick type C is a rare, complex, and progressive genetic disorder with manifestations that can vary greatly from patient to patient. To fully comprehend the severity of the disease and the therapeutic challenges it poses, it is essential understand both its biological mechanisms and its main clinical consequences.
Origin
Niemann-Pick type C (NPC) is caused by mutations in the NPC1 or NPC2 genes, leading to impaired transport of cholesterol and other lipids within cells. This defect results in abnormal accumulations of these substances in multiple organs, particularly in the central nervous system, causing progressive and irreversible degeneration.
Clinical Profile
The disease presents significant clinical variability. Symptoms and age of onset can differ widely from one patient to the other, even within the same family. While some forms appear in infancy and progress rapidly, others develop later, and with a slower progression – sometimes into early adulthood. In most cases, symptoms begin in childhood, progressing to severe complications during adolescence or early adulthood.
Key Figures About Niemann-Pick type C Disease
The actual number is estimated to be closer to 10,000, due to the disease’s complex presentation, although there are currently only about 3,500 patients worldwide
Aspiration pneumonia associated with swallowing disorders is the leading cause of death in these patients.
4 years
The average time to receive a diagnosis
4
Clinical forms based on the age at symptom onset
71%
of patients are pediatric cases (approximately)
70%
of patients experience swallowing disorders
TX01 is the new formulation of an already approved treatment for rare neurological disorders,
such as Niemann-Pick type C and Gaucher diseases. It is designed to improve administration and dosing – particularly for vulnerable patient populations.